ライフサイエンスコーパス: nonmelanoma

1 on mutation types found in crucial genes in nonmelanoma and melanoma skin cancers.

2 also the predominant mutation found in human nonmelanoma and melanoma tumor samples in the TP53, CDKN

3 The majority of skin cancer is nonmelanoma cancer, either basal cell cancer or squamous

4 Nonmelanoma cancers may involve some ss-1 and ss-2 HPV t

5 Precise removal of nonmelanoma cancers with minimum damage to the surroundi

6 h potential utility against a broad array of nonmelanoma cancers.

7 f vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers.

8 a targetable oncogene in some, but not all, nonmelanoma cancers.

9 BRAF V600 mutations occur in various nonmelanoma cancers.

10 Recent evidence in several nonmelanoma cell systems supports the regulation of the

11 Most wt p53 (nonmelanoma) cell lines (11/12, or 92%) showed clear ind

12 s of melanoma tissue containing an excess of nonmelanoma cells.

13 ween incident primary melanoma cases and the nonmelanoma controls, the risk associated with the homoz

14 with the following two different sources of nonmelanoma controls: spouse/friend controls (n = 84) an

15 ge migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of

16 eceiving a class 1 or class 2 test result in nonmelanoma is possible.

17 its nuclear localization when compared with nonmelanoma/KB-3-1 epidermoid carcinoma cells.

18 -type (wt) p53 (5/8, or 63%) compared to the nonmelanoma lines (11/48, or 23%).

19 ults are indeed possible in the setting of a nonmelanoma malignancy.

20 y of POH to inhibit photocarcinogenesis in a nonmelanoma model of mouse skin carcinogenesis and its a

21 haracteristic (ROC) = 0.879]; melanomas from nonmelanoma pigmented lesions (ROC = 0.823); and melanom

22 fied to have cytopathology consistent with a nonmelanoma primary.

23 Finally, nonmelanoma-reactive tumor-infiltrating lymphocyte cultu

24 , 43%-73%), prostate (57%; 95% CI, 51%-63%), nonmelanoma skin (43%; 95% CI, 26%-59%), ovary (39%; 95%

25 The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n

26 than heterosexual women to report having had nonmelanoma skin cancer (2001-2005 CHIS: aOR, 0.56; 95%

27 rved being central nervous system (n = 344), nonmelanoma skin cancer (n = 278), digestive (n = 105),

28 mon type of previous cancer in the donor was nonmelanoma skin cancer (n=776) followed by central nerv

29 le of mitochondrial DNA (mtDNA) deletions in nonmelanoma skin cancer (NMSC) and in cutaneous photoagi

30 erum 25-hydroxyvitamin D levels with risk of nonmelanoma skin cancer (NMSC) and melanoma, we evaluate

31 the United States, Europe, and Australia for nonmelanoma skin cancer (NMSC) and melanoma.

32 Protective effects of UV-B radiation against nonmelanoma skin cancer (NMSC) are exerted via signaling

33 ndependently reviewed the DSCMs for residual nonmelanoma skin cancer (NMSC) before and after a brief

34 on-exposed survivors who developed an SN1 of nonmelanoma skin cancer (NMSC) had a cumulative incidenc

35 Nonmelanoma skin cancer (NMSC) has become the most commo

36 accurate measurement of the US incidence of nonmelanoma skin cancer (NMSC) has been difficult.

37 aimed to determine the risk of melanoma and nonmelanoma skin cancer (NMSC) in patients with IBD and

38 was to assess trends in mortality rates for nonmelanoma skin cancer (NMSC) in the United States.

39 Nonmelanoma skin cancer (NMSC) is the most common cancer

40 Patients with a periocular region nonmelanoma skin cancer (NMSC) or a nonperiocular NMSC c

41 ot have a greater than expected incidence of nonmelanoma skin cancer (NMSC) or other cancers, whereas

42 th 95% CIs for any incident cancer excluding nonmelanoma skin cancer (NMSC) were 1.06 (95% CI, 1.02-1

43 nd squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).

44 e intake and risks of skin cancer (overall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma

45 d higher risk than HIV-uninfected persons of nonmelanoma skin cancer (NMSC), defined as basal cell ca

46 Various treatment options exist for nonmelanoma skin cancer (NMSC), including topical agents

47 During Mohs micrographic surgery of nonmelanoma skin cancer (NMSC), inflammation in histolog

48 duced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous ce

49 ng Medicare billing codes and categorized as nonmelanoma skin cancer (NMSC), viral-linked and "other"

50 in a single patient were counted, except for nonmelanoma skin cancer (NMSC), where only the first was

51 player in the development and progression of nonmelanoma skin cancer (NMSC).

52 a and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC).

53 een used as sampling frames for ascertaining nonmelanoma skin cancer (NMSC).

54 cies (malignancies), including and excluding nonmelanoma skin cancer (NMSC); all malignancies were ex

55 in a case-control study of 191 patients with nonmelanoma skin cancer (NMSC; 81 SCC and 110 basal cell

56 ts an avoidable risk factor for melanoma and nonmelanoma skin cancer - both of which may be lethal.

57 ctrum strikingly similar to that reported in nonmelanoma skin cancer and characteristic of DNA damage

58 Diagnosis of melanoma or nonmelanoma skin cancer and frequent excisions for benig

59 present in sunlight is the primary cause of nonmelanoma skin cancer and has been implicated in the d

60 pants received a cancer diagnosis, excluding nonmelanoma skin cancer and in situ neoplasms.

61 ntial and increasing risk for SNs, including nonmelanoma skin cancer and meningiomas.

62 Increases in nonmelanoma skin cancer and nonprogressive, reversible r

63 aviolet A dramatically increases the risk of nonmelanoma skin cancer and prior exposure to psoralen+u

64 vation was clear for all main cancers except nonmelanoma skin cancer and was stronger for cancers of

65 s that beta-HPV infections may contribute to nonmelanoma skin cancer by increasing the likelihood tha

66 It is clear that melanoma and nonmelanoma skin cancer control programs combining prima

67 a causative role in ODC up-regulation during nonmelanoma skin cancer development by binding to and st

68 5 cells) to explore the regulation of ODC in nonmelanoma skin cancer development.

69 There were two reported cases of nonmelanoma skin cancer during the follow up of the tran

70 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

71 the detection of positive section margins in nonmelanoma skin cancer from 8.4% to 12.8%.

72 The incidence of both melanoma and nonmelanoma skin cancer has been increasing over the pas

73 riant was also significantly associated with nonmelanoma skin cancer in a U.K. population.

74 ated with a dose-dependent increased risk of nonmelanoma skin cancer in patients treated for psoriasi

75 play an important part in the development of nonmelanoma skin cancer in psoralen + ultraviolet A-trea

76 age/repair and prevention of photodamage and nonmelanoma skin cancer in vitiligo.

77 same cumulative dose, which may explain why nonmelanoma skin cancer incidence depends more strongly

78 Nonmelanoma skin cancer is the most common cancer in the

79 While a high risk of nonmelanoma skin cancer is well recognized in solid-orga

80 Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who re

81 squamous cell carcinoma (SCC) (often termed nonmelanoma skin cancer or keratinocyte carcinoma [KC])

82 identified Zmiz1 as a candidate oncogene in nonmelanoma skin cancer through a transposon mutagenesis

83 ative incidence of SMNs was 9.3% and that of nonmelanoma skin cancer was 6.9%.

84 A trend toward decreased risk of nonmelanoma skin cancer was found in those harboring a g

85 the 10 most common cancers in the US and of nonmelanoma skin cancer was not increased with TNFalpha

86 Nonmelanoma skin cancer was not observed among irradiate

87 An excess risk of nonmelanoma skin cancer was observed subsequent to both

88 n, 66 cases of meningioma and 1,007 cases of nonmelanoma skin cancer were diagnosed.

89 Importance: Keratinocyte carcinoma (nonmelanoma skin cancer) accounts for substantial burden

90 ohort who had no cancer diagnosis (excluding nonmelanoma skin cancer) at the start of follow-up and r

91 d who had no prior history of cancer (except nonmelanoma skin cancer) were followed prospectively for

92 of breast cancer or other cancers (excluding nonmelanoma skin cancer), and we completed a personal ba

93 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the p

94 IN OUTCOME MEASURES: Total cancer (excluding nonmelanoma skin cancer), with prostate, colorectal, and

95 most common cancer type among men (excluding nonmelanoma skin cancer).

96 and 98 patients developed cancer (excluding nonmelanoma skin cancer).

97 mary cause of skin cancer (both melanoma and nonmelanoma skin cancer).

98 -degree family history of melanoma, previous nonmelanoma skin cancer, and lifetime sunbed use.

99 feature of diseases like psoriasis, eczema, nonmelanoma skin cancer, and melanoma where differentiat

100 ve an increased incidence of viral warts and nonmelanoma skin cancer, and the presence of HPV DNA in

101 ity of Pennsylvania, who were diagnosed with nonmelanoma skin cancer, dermatophytosis, acne rosacea,

102 Nonmelanoma skin cancer, Kaposi sarcoma, and posttranspl

103 ent SMNs were thyroid cancer, breast cancer, nonmelanoma skin cancer, non-Hodgkin's lymphoma, and acu

104 et A is associated with an increased risk of nonmelanoma skin cancer, particularly squamous cell carc

105 a US population-based case-control study of nonmelanoma skin cancer, randomly selected from drivers'

106 that can reduce mortality from melanoma and nonmelanoma skin cancer, screening holds the greatest pr

107 found moderately increased SIR estimates for nonmelanoma skin cancer, smoking-related cancers, and Ho

108 e exposure to sunlight increases the risk of nonmelanoma skin cancer, the avoidance of all direct sun

109 iolet (UV) irradiation is the major cause of nonmelanoma skin cancer, the most common form of cancer

110 were adjusted based on age, sex, history of nonmelanoma skin cancer, US geographic region, and popul

111 tocols and disability, dermatitis, melanoma, nonmelanoma skin cancer, viral skin diseases, and fungal

112 role of the Fragile Histidine Triad gene in nonmelanoma skin cancer, we have used reverse transcript

113 a (MCC) is a highly malignant neuroendocrine nonmelanoma skin cancer, which is associated with the Me

114 global increase in incidence of melanoma and nonmelanoma skin cancer.

115 ell carcinomas (MCCs), an aggressive form of nonmelanoma skin cancer.

116 anding the pathogenesis of wound healing and nonmelanoma skin cancer.

117 aging nor a higher incidence for sun-induced nonmelanoma skin cancer.

118 se may offer a viable therapeutic option for nonmelanoma skin cancer.

119 nscreen use to prevent actinic keratoses and nonmelanoma skin cancer.

120 adiation in sunlight is the primary cause of nonmelanoma skin cancer.

121 t ranged from 48.7% for myeloma to 31.4% for nonmelanoma skin cancer.

122 llowing UV irradiation, the primary cause of nonmelanoma skin cancer.

123 the major risk factor for the development of nonmelanoma skin cancer.

124 c has been associated with increased risk of nonmelanoma skin cancer.

125 psoriasis patients are at increased risk for nonmelanoma skin cancer.

126 on plays a critical role in the induction of nonmelanoma skin cancer.

127 ith no previous history of cancer other than nonmelanoma skin cancer.

128 global increase in incidence of melanoma and nonmelanoma skin cancer.

129 sion, which contribute to the development of nonmelanoma skin cancer.

130 %]), attributable to the higher incidence of nonmelanoma skin cancer.

131 organ transplants have an increased risk for nonmelanoma skin cancer.

132 quitous in skin and has been associated with nonmelanoma skin cancer.

133 porine have an increased risk for developing nonmelanoma skin cancer.

134 bronchus, and lung; malignant skin melanoma; nonmelanoma skin cancer; breast; cervical; uterine; ovar

135 The primary end point was the number of new nonmelanoma skin cancers (i.e., basal-cell carcinomas pl

136 Excluding nonmelanoma skin cancers (n = 19) and carcinoma-in-situ

137 Nonmelanoma skin cancers (NMSC) are among the most commo

138 V) have been suspected to be carcinogenic in nonmelanoma skin cancers (NMSC), but the basis for poten

139 Cancer registries usually exclude nonmelanoma skin cancers (NMSC), despite the large popul

140 Nonmelanoma skin cancers (NMSCs) are the most common can

141 ous basal cell and squamous cell carcinomas (nonmelanoma skin cancers (NMSCs)), data are insufficient

142 ght to be involved in the initiation of some nonmelanoma skin cancers (NMSCs), particularly in patien

143 des further evidence that for primary facial nonmelanoma skin cancers (NMSCs), recurrence rates with

144 neoplasms, increases the risk of developing nonmelanoma skin cancers (NMSCs).

145 with briakinumab vs. placebo, respectively), nonmelanoma skin cancers (NMSCs; four vs. zero squamous

146 e and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-r

147 Two nonmelanoma skin cancers and two major adverse cardiovas

148 Nonmelanoma skin cancers are among the most common human

149 More than a million cases of nonmelanoma skin cancers are diagnosed every year.

150 ecent dramatic increases in the incidence of nonmelanoma skin cancers are largely attributable to hig

151 eningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference ch

152 ll effect of screening for both melanoma and nonmelanoma skin cancers has not been achieved.

153 12-month intervention period, the number of nonmelanoma skin cancers in the 6-month postintervention

154 o, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to rece

155 e finding of TRPV4 downregulation in several nonmelanoma skin cancers into context.

156 The elevated risks of nonmelanoma skin cancers might indicate an association w

157 hree patients who underwent Mohs surgery for nonmelanoma skin cancers presented between 2 and 4 weeks

158 Nonmelanoma skin cancers that required at least 3 Mohs m

159 At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% (95% confidenc

160 .44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) a

161 SMNs), and relative risks (RRs) for SMNs and nonmelanoma skin cancers were calculated.

162 Combined cancer incidence (excluding nonmelanoma skin cancers) from 1987 to 2006 was captured

163 the incidence of all-type cancer (excluding nonmelanoma skin cancers), which was evaluated using Kap

164 rt members, 730 reported 802 SMNs (excluding nonmelanoma skin cancers).

165 These included 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, a

166 Excluding nonmelanoma skin cancers, 55 second cancers were seen in

167 rs, six non-MDS hematologic malignancies, 39 nonmelanoma skin cancers, and 68 cases of MDS/acute myel

168 Administration approved for the treatment of nonmelanoma skin cancers, but it has limited activity ag

169 Nonmelanoma skin cancers, in particular cutaneous squamo

170 lomaviruses (HPVs) have been associated with nonmelanoma skin cancers, particularly in immunocompromi

171 an papilloma virus infections and associated nonmelanoma skin cancers, providing additional genetic a

172 Nonmelanoma skin cancers, such as basal-cell carcinoma a

173 ent of precancerous skin lesions and certain nonmelanoma skin cancers.

174 lignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers.

175 the most prevalent mutations found in human nonmelanoma skin cancers.

176 n phenotypes and development of melanoma and nonmelanoma skin cancers.

177 or subsequent malignancies, meningiomas, and nonmelanoma skin cancers.

178 ic receptors as a new treatment modality for nonmelanoma skin cancers.

179 a-HPVs) may contribute to the development of nonmelanoma skin cancers.

180 a or skin squamous cell carcinoma or cSCC or nonmelanoma skin neoplasms." Study Selection: Articles w

181 Animals were monitored for the appearance of nonmelanoma skin tumors (NMSTs) and melanocytic hyperpla

182 with accelerated and increased formation of nonmelanoma skin tumors during chemical carcinogenesis.

183 The incidence of malignancy (excluding nonmelanoma skin tumors) was determined in these 1886 pa

184 s are frequently observed in the p53 gene of nonmelanoma skin tumors.

185 ould efficiently recognize NY-ESO-1-positive nonmelanoma tumor cell lines.

186 c reactivity against a range of melanoma and nonmelanoma tumor cells.

187 but not HLA-mismatched melanoma or gp100(-) nonmelanoma tumor lines.

188 monstration of the successful treatment of a nonmelanoma tumor using TCR-transduced T cells.

189 Similar efforts for nonmelanoma tumors have had limited success with few ant

190 genesis, instead inducing the development of nonmelanoma tumors that included squamous cell carcinoma

191 a distinct syngeneic melanoma, but not with nonmelanoma tumors.

192 relating features of pigmented NM vs nodular nonmelanoma were peripheral black dots/globules, multipl